
$766M+102% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Revenue reached $766M in 2025, compounding +80% a year since 2022 though the pace has cooled. The trailing twelve months are already running at $379M, behind the last full year.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
$364MFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Net income was $364M in 2025, against $-146M the year before. Earnings per share moved -429% over the last twelve months. Trailing twelve-month profit stands at $-998M.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
+102.2%revenue growth, FY 2025
→Revenue grew +102% in 2025 against a five-year average of +169%.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
$-606MFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→The business consumed $606M of cash in 2025 after investment. Growth is being funded from the balance sheet, not from operations.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Free cash flow is negative, so no share of revenue is currently converting to spare cash. Every sales dollar is being reinvested or consumed.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→The biggest claim on each sales dollar is capital spending, at 19% of revenue (stock compensation 6%, research and development 1%). That share has risen since 2022, so the cost of competing is climbing.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Operating margin widened 70 points to 42% since 2022. After everything, 48 cents of each sales dollar reaches net profit.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→ROE of -131% and ROCE of 10% sit close together, so the returns come from the business itself rather than from borrowing.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
8.6xP/S today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→At 8.6x sales, the market is paying +21% more than CLSK's own 5-year median of 7.1x. Expectations are elevated, so more has to go right to justify the price.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
-19.0%FCF yield today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→Every dollar of market value currently buys -19.0% of annual free cash flow, more than its 5-year median of -7.0% - the cash is cheaper than usual.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→Debt of $1.8B sits against $203M of cash, or 2.3x shareholders' equity. Earnings don't currently cover the interest bill at all.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→The company's own capital shrank from $809M in 2023 to $761M (-6%). Buybacks or losses are drawing the buffer down - the distinction matters.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→Shareholders received $145M in buybacks in 2025. Stock compensation issued $45M of new shares in the same year, offsetting 31% of that.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→The share count grew 46.5% in 2025. Your slice of the company shrinks by that much each year unless earnings grow faster.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→CLSK earns 10.0% on the capital it employs, comfortably above the 10% most investors treat as the cost of capital. That is the highest in CLSK's filed history.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→CLSK issued +20% more shares from 2021 to 2025, but revenue per share still rose +1527%. The dilution bought more growth than it cost existing holders.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
→Insiders sold $1M on the open market and bought nothing. Many sales are pre-scheduled diversification rather than a view on the price. A further 57 filings were grants, option exercises or tax withholding, which say nothing either way.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30